| Active substance |
Silodosin |
| Also known as |
KMD-3213 |
| Blood pressure |
May cause a decrease in blood pressure |
| Chemical name |
1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide |
| Dosage (medical) |
Typically 8 mg once daily |
| Dosage (sports) |
Not applicable |
| Effects |
Improves urinary flow and symptoms associated with benign prostatic hyperplasia (BPH) |
| Formula |
C25H32F3N3O4 |
| Half-life |
Approximately 13 hours |
| Hepatotoxicity |
Low |
| Lab Test |
Not specific |
| Main action |
Reduces smooth muscle contraction in the prostate and urethra |
| Side effects |
Dizziness, orthostatic hypotension, retrograde ejaculation, headache, diarrhea |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Substance class |
Alpha-1 adrenergic receptor antagonist |
| Trade name |
Rapaflo, Silodyx |
| Use in sports |
None |
| Water Retention |
Minimal to none |
| Manufacturer |
Recordati |
| Packing |
30 tabs (4mg/tab) |
